ASH 2018 | Understanding the value of MRD in CLL: results from MURANO
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
Arnon Kater, MD, PhD, of the University of Amsterdam, Amsterdam, Netherlands, discusses the results of the Phase III MURANO study (NCT02005471), specifically the first prospective data on the impact of peripheral blood measurable residual disease (MRD) on long-term clinical outcomes following venetoclax plus rituximab (VenR) vs. bendamustine plus rituximab (BR) in chronic lymphocytic leukemia (CLL) patients. After 6 months of combination treatment with VenR, patients had lower MRD levels compared to the BR group. The same result was still seen after 2 years of treatment. What is more, low MRD acted as a predictive marker for clinical outcome. It is clear from these results that MRD is a valuable tool in the management of CLL. This interview was filmed at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Get great new content delivered to your inboxSign up